Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction.

Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ, Mueller KT, Good CR, Berger SL, Shalem O, Weitzman MD, Frey NV, Maude SL, Grupp SA, June CH, Gill S, Ruella M.

Cancer Discov. 2020 Jan 30. pii: CD-19-0813. doi: 10.1158/2159-8290.CD-19-0813. [Epub ahead of print]

PMID:
32001516
2.

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor positive cells.

Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey AD, Hong SJ, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, Gill S.

Blood. 2019 Nov 8. pii: blood.2019001859. doi: 10.1182/blood.2019001859. [Epub ahead of print]

PMID:
31703119
3.

Single-cell analysis reveals fibroblast heterogeneity and myeloid-derived adipocyte progenitors in murine skin wounds.

Guerrero-Juarez CF, Dedhia PH, Jin S, Ruiz-Vega R, Ma D, Liu Y, Yamaga K, Shestova O, Gay DL, Yang Z, Kessenbrock K, Nie Q, Pear WS, Cotsarelis G, Plikus MV.

Nat Commun. 2019 Feb 8;10(1):650. doi: 10.1038/s41467-018-08247-x.

4.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.

Nat Med. 2018 Oct;24(10):1499-1503. doi: 10.1038/s41591-018-0201-9. Epub 2018 Oct 1.

5.

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.

Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S.

Cell. 2018 May 31;173(6):1439-1453.e19. doi: 10.1016/j.cell.2018.05.013. Epub 2018 May 31.

6.

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S.

Cancer Discov. 2017 Oct;7(10):1154-1167. doi: 10.1158/2159-8290.CD-16-0850. Epub 2017 Jun 2.

7.

Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.

Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.

Blood. 2017 Apr 27;129(17):2395-2407. doi: 10.1182/blood-2016-08-736041. Epub 2017 Feb 28.

8.

Improved surfaceome coverage with a label-free nonaffinity-purified workflow.

Glisovic-Aplenc T, Gill S, Spruce LA, Smith IR, Fazelinia H, Shestova O, Ding H, Tasian SK, Aplenc R, Seeholzer SH.

Proteomics. 2017 Apr;17(7). doi: 10.1002/pmic.201600344. Epub 2017 Mar 6.

9.

High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.

Chiang MY, Wang Q, Gormley AC, Stein SJ, Xu L, Shestova O, Aster JC, Pear WS.

Blood. 2016 Nov 3;128(18):2229-2240. Epub 2016 Sep 26.

10.

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.

Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH, Gill S.

Leukemia. 2017 Jan;31(1):246-248. doi: 10.1038/leu.2016.262. Epub 2016 Sep 28. No abstract available.

PMID:
27677739
11.

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, Gill S.

J Clin Invest. 2016 Oct 3;126(10):3814-3826. doi: 10.1172/JCI87366. Epub 2016 Aug 29.

12.

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA.

Clin Cancer Res. 2016 Jun 1;22(11):2684-96. doi: 10.1158/1078-0432.CCR-15-1527. Epub 2016 Jan 27.

13.

Off-Target V(D)J Recombination Drives Lymphomagenesis and Is Escalated by Loss of the Rag2 C Terminus.

Mijušković M, Chou YF, Gigi V, Lindsay CR, Shestova O, Lewis SM, Roth DB.

Cell Rep. 2015 Sep 22;12(11):1842-52. doi: 10.1016/j.celrep.2015.08.034. Epub 2015 Sep 10.

14.

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.

Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S.

Leukemia. 2015 Aug;29(8):1637-47. doi: 10.1038/leu.2015.52. Epub 2015 Feb 27.

15.

RAG2 mutants alter DSB repair pathway choice in vivo and illuminate the nature of 'alternative NHEJ'.

Gigi V, Lewis S, Shestova O, Mijušković M, Deriano L, Meng W, Luning Prak ET, Roth DB.

Nucleic Acids Res. 2014 Jun;42(10):6352-64. doi: 10.1093/nar/gku295. Epub 2014 Apr 20.

16.

The Notch1 transcriptional activation domain is required for development and reveals a novel role for Notch1 signaling in fetal hematopoietic stem cells.

Gerhardt DM, Pajcini KV, D'altri T, Tu L, Jain R, Xu L, Chen MJ, Rentschler S, Shestova O, Wertheim GB, Tobias JW, Kluk M, Wood AW, Aster JC, Gimotty PA, Epstein JA, Speck N, Bigas A, Pear WS.

Genes Dev. 2014 Mar 15;28(6):576-93. doi: 10.1101/gad.227496.113.

17.

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M.

Blood. 2014 Apr 10;123(15):2343-54. doi: 10.1182/blood-2013-09-529537. Epub 2014 Mar 4. Erratum in: Blood. 2016 Nov 24;128(21):2585.

18.

Divergent effects of supraphysiologic Notch signals on leukemia stem cells and hematopoietic stem cells.

Chiang MY, Shestova O, Xu L, Aster JC, Pear WS.

Blood. 2013 Feb 7;121(6):905-17. doi: 10.1182/blood-2012-03-416503. Epub 2012 Oct 31.

19.

A critical role for TCF-1 in T-lineage specification and differentiation.

Weber BN, Chi AW, Chavez A, Yashiro-Ohtani Y, Yang Q, Shestova O, Bhandoola A.

Nature. 2011 Aug 3;476(7358):63-8. doi: 10.1038/nature10279.

20.

Identification of Flt3⁺CD150⁻ myeloid progenitors in adult mouse bone marrow that harbor T lymphoid developmental potential.

Chi AW, Chavez A, Xu L, Weber BN, Shestova O, Schaffer A, Wertheim G, Pear WS, Izon D, Bhandoola A.

Blood. 2011 Sep 8;118(10):2723-32. doi: 10.1182/blood-2010-09-309989. Epub 2011 Jul 26.

Supplemental Content

Loading ...
Support Center